trending Market Intelligence /marketintelligence/en/news-insights/trending/4jIDDPPyCrhacO5JvIYaiQ2 content esgSubNav
In This List

AstraZeneca, Ionis heart disease drug advances into preclinical development

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


AstraZeneca, Ionis heart disease drug advances into preclinical development

Ionis Pharmaceuticals Inc. said it advanced its lead drug candidate, renamed AZD8233, into preclinical development.

The drug, developed under a strategic collaboration with AstraZeneca PLC, is designed to treat cardiovascular disease.

Ionis received a $25 million milestone payment from AstraZeneca following the development. Ionis is also eligible to receive up to $300 million in additional milestone payments as the drug advances in development, as well as royalties from the drug's sales.

AstraZeneca will be responsible for developing and commercializing AZD8233.